References
- Grabar S, Costagliola D. Epidemiology of Kaposi’s Sarcoma. Cancers. 2021;13(22):5692. doi:10.3390/cancers13225692
- Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma. Curr Opin Oncol. 2020;32(2):122–128. doi:10.1097/CCO.0000000000000601
- Poizot-Martin I, Gigeon S, Palich R, et al. Immune reconstitution inflammatory syndrome associated Kaposi Sarcoma. Cancers. 2022;14(4):986. doi:10.3390/cancers14040986
- Volkow P, Cesarman-Maus G, Garciadiego-Fossas P, et al. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma. AIDS Res Ther. 2017;14(1):30. doi:10.1186/s12981-017-0156-9
- Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol. 2017;18(4):529–539. doi:10.1007/s40257-017-0270-4
- Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9(6):336–388. doi:10.1111/j.1468-1293.2008.00608.x
- Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11(4):223–238. doi:10.1038/nrclinonc.2014.31
- Krell J, Stebbing J. Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):373–375. doi:10.1200/JCO.2013.53.7126
- Goff CB, Dasanu CA. Changing therapeutic landscape in advanced Kaposi sarcoma: current state and future directions. J Oncol Pharm Pract. 2023;29(4):917–926. doi:10.1177/10781552221148417
- Mosca L, Ilari A, Fazi F, et al. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updates. 2021;54:100742. doi:10.1016/j.drup.2020.100742
- Christensen SB. Drugs that changed society: microtubule-targeting agents belonging to taxanoids, macrolides and non-ribosomal peptides. Molecules. 2022;27(17):5648. doi:10.3390/molecules27175648
- Gallego-Jara J, Lozano-Terol G, Sola-Mart Nez RA, et al. A compressive review about taxol(®): history and future challenges. Molecules. 2020;25(24):5986. doi:10.3390/molecules25245986
- Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200–4205. doi:10.1158/1078-0432.CCR-07-4592
- Neesse A, Frese KK, Chan DS, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 2014;63(6):974–983. doi:10.1136/gutjnl-2013-305559
- Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J Clin Oncol. 2012;30(17):2055–2062. doi:10.1200/JCO.2011.39.5848
- Li BX, Chen XJ, Ding TJ, et al. Potentially overestimated efficacy of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in breast cancer: a systemic review and meta-analysis. J Cancer. 2021;12(17):5164–5172. doi:10.7150/jca.59794
- Ramanathan RK, Goldstein D, Korn RL, et al. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 2016;27(4):648–653. doi:10.1093/annonc/mdw020